The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Giuseppe Criseo - One of the best experts on this subject based on the ideXlab platform.
-
disseminated nosocomial fungal infection by Aureobasidium pullulans var melanigenum a case report
Journal of Clinical Microbiology, 2003Co-Authors: Giuseppe Bolignano, Giuseppe CriseoAbstract:We report on a rare case of disseminated nosocomial fungal infection due to Aureobasidium pullulans var. melanigenum in a severely traumatized patient. Repeated blood and urine cultures yielded multicellular filamentous hyphal structures of varying size accompanied by budding yeast-like-cells of ellipsoidal morphology. The patient became asymptomatic after fluconazole therapy.
Haoshuai Li - One of the best experts on this subject based on the ideXlab platform.
-
optimization of medium and cultivation conditions for alkaline protease production by the marine yeast Aureobasidium pullulans
Bioresource Technology, 2007Co-Authors: Peng Wang, Haoshuai LiAbstract:Abstract A yeast strain, Aureobasidium pullulans , which could produce the high yield of protease was isolated from sediment of saltern in Qingdao, China. Maximum production of enzyme (623.1 U/mg protein; 7.2 U/ml) was obtained in a medium containing 2.5 g soluble starch and 2.0 g NaNO 3 , 100 ml seawater, initial pH 6.0, after fermentation at 24.5 °C for 30 h. The protease had the highest activity at pH 9.0 and 45 °C.
Deanna A Sutton - One of the best experts on this subject based on the ideXlab platform.
-
in vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans
Antimicrobial Agents and Chemotherapy, 2014Co-Authors: Javad M Najafzadeh, Deanna A Sutton, Saradeghi M Keisari, Hossein Zarrinfar, Sybren G De Hoog, Anuradha Chowdhary, Jacques F MeisAbstract:Aureobasidium pullulans is an unusual agent of phaeohyphomycosis. The in vitro activities of antifungals against 104 isolates of Aureobasidium pullulans var. pullulans and A. pullulans var. melanigenum revealed low MIC90s of amphotericin B, posaconazole, and itraconazole. However, they were resistant to fluconazole (≥64 μg/ml) and had high MICs of voriconazole, isavuconazole, caspofungin, and micafungin.
-
Aureobasidium pullulans var melanigenum fungemia in a pediatric patient
Medical Mycology, 2011Co-Authors: Kileen L Mershonshier, Deanna A Sutton, Sybren G De Hoog, Jaime G Deville, Shirley Delair, Annette W Fothergill, Brian L Wickes, Michael A LewinskiAbstract:This report describes a chronically ill child who presented with high fever and was diagnosed with catheter-related sepsis. Aureobasidium pullulans variety melanigenum, a dematiaceous fungus that rarely causes opportunistic infections, was recovered from multiple blood cultures. Antifungal susceptibilities were performed and the minimum inhibitory concentration (MIC) for fluconazole was 64 mg/l, suggestive of fluconazole resistance. The patient made a full recovery after removal of the catheter line and treatment with liposomal amphotericin B. This is the first case report of an elevated in vitro fluconazole MIC of an A. pullulans isolate and only the third case of successful treatment of A. pullulans fungemia.
Sybren G De Hoog - One of the best experts on this subject based on the ideXlab platform.
-
in vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans
Antimicrobial Agents and Chemotherapy, 2014Co-Authors: Javad M Najafzadeh, Deanna A Sutton, Saradeghi M Keisari, Hossein Zarrinfar, Sybren G De Hoog, Anuradha Chowdhary, Jacques F MeisAbstract:Aureobasidium pullulans is an unusual agent of phaeohyphomycosis. The in vitro activities of antifungals against 104 isolates of Aureobasidium pullulans var. pullulans and A. pullulans var. melanigenum revealed low MIC90s of amphotericin B, posaconazole, and itraconazole. However, they were resistant to fluconazole (≥64 μg/ml) and had high MICs of voriconazole, isavuconazole, caspofungin, and micafungin.
-
Aureobasidium pullulans var melanigenum fungemia in a pediatric patient
Medical Mycology, 2011Co-Authors: Kileen L Mershonshier, Deanna A Sutton, Sybren G De Hoog, Jaime G Deville, Shirley Delair, Annette W Fothergill, Brian L Wickes, Michael A LewinskiAbstract:This report describes a chronically ill child who presented with high fever and was diagnosed with catheter-related sepsis. Aureobasidium pullulans variety melanigenum, a dematiaceous fungus that rarely causes opportunistic infections, was recovered from multiple blood cultures. Antifungal susceptibilities were performed and the minimum inhibitory concentration (MIC) for fluconazole was 64 mg/l, suggestive of fluconazole resistance. The patient made a full recovery after removal of the catheter line and treatment with liposomal amphotericin B. This is the first case report of an elevated in vitro fluconazole MIC of an A. pullulans isolate and only the third case of successful treatment of A. pullulans fungemia.
Timothy D. Leathers - One of the best experts on this subject based on the ideXlab platform.
-
Inactivation of virginiamycin by Aureobasidium pullulans.
Biotechnology Letters, 2017Co-Authors: Timothy D. Leathers, Joseph O. Rich, Melinda S. Nunnally, Amber M. AndersonAbstract:To test the inactivation of the antibiotic, virginiamycin, by laccase-induced culture supernatants of Aureobasidium pullulans. Fourteen strains of A. pullulans from phylogenetic clade 7 were tested for laccase production. Three laccase-producing strains from this group and three previously identified strains from clade 5 were compared for inactivation of virginiamycin. Laccase-induced culture supernatants from clade 7 strains were more effective at inactivation of virginiamycin, particularly at 50 °C. Clade 7 strain NRRL Y-2567 inactivated 6 µg virginiamycin/ml within 24 h. HPLC analyses indicated that virginiamycin was degraded by A. pullulans. A. pullulans has the potential for the bioremediation of virginiamycin-contaminated materials, such as distiller’s dry grains with solubles (DDGS) animal feed produced from corn-based fuel ethanol production.
-
Polyols, not sugars, determine the structural diversity of anti-streptococcal liamocins produced by Aureobasidium pullulans strain NRRL 50380.
The Journal of Antibiotics, 2016Co-Authors: Neil P. J. Price, Kenneth M. Bischoff, Timothy D. Leathers, Allard A. Cossé, Pennapa ManitchotpisitAbstract:Polyols, not sugars, determine the structural diversity of anti-streptococcal liamocins produced by Aureobasidium pullulans strain NRRL 50380
-
Phylogenetic classification of Aureobasidium pullulans strains for production of feruloyl esterase.
Biotechnology Letters, 2016Co-Authors: Joseph O. Rich, Pennapa Manitchotpisit, Stephen W. Peterson, Timothy D. Leathers, Amber M. AndersonAbstract:Objective The objective was to phylogenetically classify diverse strains of Aureobasidium pullulans and determine their production of feruloyl esterase.
-
Production of novel types of antibacterial liamocins by diverse strains of Aureobasidium pullulans grown on different culture media.
Biotechnology Letters, 2015Co-Authors: Timothy D. Leathers, Pennapa Manitchotpisit, Kenneth M. Bischoff, Neil P. J. Price, Christopher D. SkoryAbstract:Objectives To compare production of antibacterial liamocins (polyol lipids) by diverse strains of Aureobasidium pullulans grown on different culture media.
-
liamocin oil from Aureobasidium pullulans has antibacterial activity with specificity for species of streptococcus
The Journal of Antibiotics, 2015Co-Authors: Kenneth M. Bischoff, Timothy D. Leathers, Neil P. J. Price, Pennapa ManitchotpisitAbstract:Liamocin oil from Aureobasidium pullulans NRRL 50380 was tested for antibacterial activity. Liamocins inhibited growth of Streptococcus agalactiae, S. uberis, S. mitis, S. infantarius, and S. mutans, with minimum inhibitory concentrations from 20 'g/ml to 78 'g/ml. Enterococcus faecalis was less susceptible (MIC = 312 'g/ml), while Staphylococcus aureus, Lactobacillus fermentum, Escherichia coli, and Pseudomonas aeruginosa had MICs > 1,250 'g/ml. Liamocins may be developed as a narrow spectrum antimicrobial agent that targets streptococcal pathogens.